Answers are grounded in this paper and cite their sources.
BACKGROUND: The risk of hepatocellular carcinoma (HCC) and net benefit of surveillance can differ between patients with cirrhosis. We compared the benefits and harms of HCC surveillance across risk strata in patients with cirrhosis. METHODS: We leveraged a cohort of patients with cirrhosis from a pragmatic randomized controlled trial of HCC surveillance outreach enrolled between March 2018 and April 2021. Patients were stratified into low-, intermediate-, and high-risk categories based on published thresholds for three validated clinical risk scores. We calculated HCC incidence rates and moderate-to-severe physical harms for each risk stratum. RESULTS: Of 2,142 patients with cirrhosis followed for a median of 36 months, 84 developed HCC and 90 (4.2%) experienced moderate-to-severe physical harm. The risk scores each achieved moderate discrimination for the prediction of HCC, with c-statistics ranging from 0.60 to 0.68. HCC incidence significantly increased from low- to high-risk categories across all clinical risk scores, whereas surveillance-related harms were similar across all risk strata. The net benefit (weighted benefit vs. harm assessment) was highest for high-risk stratum (range 2.8-3.9) and lowest for low-risk stratum (range from -0.3 to 0.1), indicating the greatest net benefit for high-risk patients and less clear benefit in low-risk patients. Despite variation in the overall value of surveillance across risk categories, adherence to surveillance was low (median proportion time covered by imaging: 32.3%) and not proportional to HCC risk. CONCLUSIONS: The net benefit of HCC surveillance significantly differs by HCC risk category in patients with cirrhosis, providing an impetus for risk-stratified surveillance approaches. IMPACT AND IMPLICATIONS: Surveillance is recommended in all patients with cirrhosis, although its net benefit can differ between patients based on risk of HCC. Using three validated clinical risk scores in 2,142 patients with cirrhosis followed for a median of 36 months, we found that HCC incidence significantly increased from low- to high-risk categories, whereas surveillance-related harms were similar across all risk strata. Therefore, the net benefit of HCC surveillance was greatest for high-risk individuals and lowest for low-risk stratum. These data provide an impetus to transition from one-size-fits-all surveillance to a risk-stratified or precision approach. CLINICAL TRIALS REGISTRATION: NCT02582918.
No takes yet. Share an insight, caveat, or question.
Patel et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: